Dec. 4 (UPI) -- The Exzolt Cattle-CA1, aka Fluralaner, topical drug has received conditional approval from federal regulators to prevent and treat New World Screwworm and cattle fever tick infestations.
The Food and Drug Administration announced the approval on Thursday and said the topical drug will help to prevent NWS larval infestations and treat and control cattle fever in beef cattle that are at least two months old and young dairy cows that are younger than 20 months of age.
"This conditional approval gives cattle producers a new toll to combat two parasites threatening the well-being of cattle in the United States," FDA Commissioner Marty Makary said.
"Although NWS has not been detected in the United States, the cattle fever tick is here," Makary explained. "This is the first drug conditionally approved by the FDA specifically for the control and treatment of cattle fever tick."
Related
